Novimmune bolsters senior management team to help advance lead program

19 September 2016
novimmune-large

Privately-held Swiss biotech firm Novimmune has added two experienced pharma executives to its senior management team.

The Geneva-based company, which is focused on the discovery and development of antibody-based drugs, has appointed Sven Zimmermann as its chief financial officer (CFO) and Mylène Fleurant as global head of quality.

Novimmune chief executive Eduard Holdener said: “We continue to add capabilities to our strong and experienced management team to support our growth strategy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology